Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Feb 17;12(1):19–27. doi: 10.1080/19336918.2017.1288789

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Author(s). Published with license by Taylor & Francis

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 4. — Sorafenib treatment in liver cells, hepatoma cells, and plectin knockdown-liver cells. (A) Sorafenib (from 0 to 10 μM) was applied in Chang liver cells, PLC/PRF/5 and HepG2 cell lines. Cell viabilities were determined in 72 hours. The data showed that HepG2 cells were more sensitive to sorafenib treatment than Chang liver cells and PLC/PRF/5 cell lines were. (B) Reduction in mRNA expression of Chang liver cells was associated with transient knockdown of plectin. (C) Sorafenib (10 μM) was applied in mock and plectin knockdown-Chang liver cell respectively. Plectin knockdown-cells revealed significantly higher sensitivity to sorafenib treatment (p < 0.05).